Univariate and multivariable analyses of prognostic factors associated with PFS and OS
| PFS . | . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |||
| Treatment (ref = R-ACVBP) | |||||||
| R-CHOP14 | 211 | 0.702 (0.278-1.771) | .5 | ||||
| R-CHOP21 | 1.385 (0.578-3.319) | .5 | |||||
| LDH > ULN | 210 | 1.157 (0.444-3.013) | .8 | ||||
| IPI of 3 to 5 | 205 | 1.988 (0.957-4.132) | .07 | ||||
| MTV ≥ 360 cm3 | 162 | 2.449 (1.06-5.661) | .04 | 95 | 2.409 (0.69-8.413) | .2 | |
| PDL1high/PDL2high | 120 | 4.292 (1.437-12.817) | .009 | 95 | 5.222 (1.352-20.168) | .02 | |
| B2M mutated | 128 | 9.455 (1.249-71.595) | .03 | ||||
| PFS . | . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |||
| Treatment (ref = R-ACVBP) | |||||||
| R-CHOP14 | 211 | 0.702 (0.278-1.771) | .5 | ||||
| R-CHOP21 | 1.385 (0.578-3.319) | .5 | |||||
| LDH > ULN | 210 | 1.157 (0.444-3.013) | .8 | ||||
| IPI of 3 to 5 | 205 | 1.988 (0.957-4.132) | .07 | ||||
| MTV ≥ 360 cm3 | 162 | 2.449 (1.06-5.661) | .04 | 95 | 2.409 (0.69-8.413) | .2 | |
| PDL1high/PDL2high | 120 | 4.292 (1.437-12.817) | .009 | 95 | 5.222 (1.352-20.168) | .02 | |
| B2M mutated | 128 | 9.455 (1.249-71.595) | .03 | ||||
| OS . | . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |||
| Treatment (ref = R-ACVBP) | |||||||
| R-CHOP14 | 211 | Infinite | |||||
| R-CHOP21 | 1.294 (0.461-3.634) | .6 | |||||
| LDH > ULN | 210 | 1.737 (0.399-7.559) | .5 | ||||
| IPI score of 3 to 5 | 205 | 2.863 (1.135-7.222) | .03 | 94 | 1.199 (0.258-5.562) | .8 | |
| MTV ≥ 360 cm3 | 162 | 4.391 (1.397-13.802) | .01 | 94 | 3.032 (0.563-16.326) | .2 | |
| PDL1high/PDL2high | 120 | 8.244 (1.711-39.715) | .009 | 94 | 10.368 (1.204-89.267) | .03 | |
| B2M mutated | 128 | 5.786 (0.732-45.709) | .1 | ||||
| OS . | . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |||
| Treatment (ref = R-ACVBP) | |||||||
| R-CHOP14 | 211 | Infinite | |||||
| R-CHOP21 | 1.294 (0.461-3.634) | .6 | |||||
| LDH > ULN | 210 | 1.737 (0.399-7.559) | .5 | ||||
| IPI score of 3 to 5 | 205 | 2.863 (1.135-7.222) | .03 | 94 | 1.199 (0.258-5.562) | .8 | |
| MTV ≥ 360 cm3 | 162 | 4.391 (1.397-13.802) | .01 | 94 | 3.032 (0.563-16.326) | .2 | |
| PDL1high/PDL2high | 120 | 8.244 (1.711-39.715) | .009 | 94 | 10.368 (1.204-89.267) | .03 | |
| B2M mutated | 128 | 5.786 (0.732-45.709) | .1 | ||||
Regarding OS, because no deaths were observed in the R-CHOP14 group, the HR was infinite. Multivariate analysis was performed with selected relevant variables that were most significantly associated with PFS or OS in univariate analysis. Performing multivariate analysis for PFS with 3 variables significantly associated with outcome in univariate analysis (MTV, B2M, and PDL1/PDL2 status) was not possible because of a convergence issue of the model (related to missing data), leading to a nonestimation of the coefficient for B2M. Therefore, multivariate analysis for PFS excluded the B2M variable.
LDH, lactate dehydrogenase; ref, reference; ULN, upper limit of normal laboratory value.